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A B S T R A C T
Background: Blood glucose level at admission in ST-segment elevation myocardial infarction (STEMI) is a
predictor of heart failure and mortality. A previous study showed the association between hyperglycemia
and microvascular dysfunction using myocardial contrast echocardiography. Late gadolinium enhance-
ment (LGE) cardiovascular magnetic resonance imaging (CMR) can demonstrate microvascular obstruction
(MVO) as the area with hypointense core within LGE. This study was performed to investigate the
association between hyperglycemia at admission and MVO using CMR in patients with STEMI.
Methods: Ninety-three patients with ﬁrst STEMI who were treated by percutaneous coronary
intervention (PCI) were included. CMR was performed within 7 days after PCI. Venous blood was
collected routinely immediately after admission for plasma glucose determination before intravenous
injection of some medications. Samples were analyzed in the hospital’s central laboratory. We
performed LGE-CMR to assess the presence of MVO.
Results: MVO was found in 34 (37%) of all 93 patients; their glucose level at admission was signiﬁcantly
higher than that of patients who did not exhibit MVO [204 (153–267) mg/dl vs. 157 (127–200) mg/dl,
p = 0.002]. There were no differences in glycosylated hemoglobin and incidence of diabetes mellitus
between the two groups. A multivariable logistic regression analysis showed that glucose level at
admission was an independent predictor of MVO (odds ratio, 1.014; 95% conﬁdence interval, 1.004 to
1.023; p = 0.006). The glucose level at admission 190 mg/dl was the best threshold value for identifying
MVO. The occurrence of MVO was signiﬁcantly higher in the patients with glucose level at admission
3190 mg/dl compared with the patients with glucose level <190 mg/dl [18 (53%) vs. 16 (27%), p = 0.023].
Conclusions: Hyperglycemia at admission in STEMI patients who were treated by PCI was associated
with the presence of MVO assessed by LGE-CMR.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Primary percutaneous coronary intervention (PCI) is an
established reperfusion therapy for acute myocardial infarctionDOI of commentary article: http://dx.doi.org/10.1016/j.jjcc.2014.11.012
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http://dx.doi.org/10.1016/j.jjcc.2014.10.013
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights(AMI) [1]. However, patency of the epicardial coronary artery does
not always guarantee salvage of the myocardium at risk for
ischemia. Patients with no-reﬂow phenomenon which is likely to
be caused by microvascular obstruction (MVO) are associated with
poor clinical outcomes when compared with patients with a good
ﬂow after reperfusion [2,3]. Late gadolinium enhancement (LGE)
cardiovascular magnetic resonance imaging (CMR) was introduced
as an effective method to assess infarct size and MVO [4,5]. How-
ever, the predictor of MVO after primary PCI has not been fully
investigated. reserved.
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irrespective of a history of diabetes mellitus (DM) [6–8]. An
association between plasma glucose level at admission and an
increased risk of mortality and poor prognosis after AMI has been
reported [8–12]. As the underlying mechanisms of these deleteri-
ous effects of hyperglycemia, a previous study showed the
association between hyperglycemia at admission and microvas-
cular dysfunction using myocardial contrast echocardiography
[13]. The aim of the present study was to investigate the
association between hyperglycemia at admission and CMR-
derived MVO after primary PCI in patients with ST-segment
elevation myocardial infarction (STEMI).
Materials and methods
Study population
Between September 2011 and April 2013, we enrolled a total
of 93 patients with STEMI who were recanalized with PCI. We
carefully excluded patients with cardiogenic shock, unstable
hemodynamic status, previous myocardial infarction, previous
coronary bypass surgery, signiﬁcant renal dysfunction (glomer-
ular ﬁltration rate <30 ml/min/1.73 m2), or contraindications for
CMR such as metal implants. CMR was performed within the
ﬁrst week after PCI in all patients. A diagnosis of STEMI required
the presence of chest symptoms continuing for >30 min, ST-
segment elevation of >0.1 mV in 2 limb leads on electrocardio-
gram, and an increase in serum creatine kinase-myocardial band
(CK-MB) levels to more than twice the upper limit of normal.
Patients with a previous or current diagnosis of DM or an
abnormal oral glucose tolerance test (75 g) 5 days after
admission were deﬁned as having DM. Venous blood was
collected routinely and immediately after admission for plasma
glucose determination, before intravenous injection of some
medications. Samples were analyzed in the hospital’s central
laboratory. This study was approved by the Ethics Committee of
Wakayama Medical University and all patients gave their
written informed consent.
Primary PCI procedure
Oral aspirin (200 mg) and intravenous heparin (100 U/kg)
were administered before coronary catheterization. Thromboly-
sis was not performed for any patients. Coronary angiograms
were obtained from a standard series of 6 to 8 projections for
the left coronary artery and 2 to 3 projections for the right
coronary artery. The infarct-related lesion was identiﬁed on
the basis of the ﬁndings by a coronary angiogram as well as
an electrocardiogram and transthoracic echocardiogram. In
patients with thrombolysis in myocardial infarction (TIMI)
ﬂow grade <2, aspiration thrombectomy was performed using a
5.1-French aspiration catheter (ExportCatheter, Medtronic
Japan, Tokyo, Japan). PCI was performed using a 6-French
guiding catheter, a 0.014-inch guidewire, a monorail balloon
catheter, and a coronary stent with a conventional technique.
Using the intracoronary imaging devices, decision-making
related to the PCI strategy depended on the discretion of
individual operators. All patients received dual antiplatelet
therapy with aspirin (81 mg/day) and clopidogrel (75 mg/day)
after primary PCI.
Angiographic analysis
Coronary angiograms were reviewed by independent observers
blinded to MRI ﬁndings. The degree of perfusion was evaluated
according to TIMI criteria [14]. Collaterals were graded accordingto Rentrop’s classiﬁcation, with good collateral ﬂow deﬁned as
grade 2 or 3 [15]. No reﬂow phenomenon was deﬁned as TIMI
grade 0, 1, or 2 without mechanical obstruction on angiograms
after PCI. Reperfusion injury was deﬁned as ST-segment re-
elevation or ventricular tachycardia/ventricular ﬁbrillation just
after recanalization in this study.
CMR protocol
All CMR examinations were performed using a 1.5-T clinical
scanner (Intera Achieva; Philips Medical Systems, Best, The
Netherlands) equipped with a 32-element cardiac phased-array
coil for signal reception within the ﬁrst week after PCI, as previously
described [16]. During the examination, patients were continuously
monitored on single-lead electrocardiogram, repeated blood pres-
sure measurements, and pulse oximetry. With the patient in the
supine position, contiguous short-axis cine images covering the
left ventricle (LV) from base to apex were acquired using a standard
steady-state free-precession sequence. LGE imaging covering
the whole ventricle was required 10–15 min after intravenous
injection of 0.1 mmol/kg gadolinium diethylenetriamine penta-
acetic acid (Magnevist, Schering, Berlin, Germany). We used a 3-D
inversion-recovery turbo gradient echo sequence, and images
were obtained during an end-expiratory breath-hold. Scan param-
eters were as follows: TR, 4.1 ms; TE, 1.25 ms; ﬂip angle, 158;
FOV, 350 mm  350 mm; partial echo; matrix, 224  256; and
spatial resolution, 1.56 mm  2.24 mm  10 mm reconstructed to
0.68 mm  20.68 mm  5 mm. Inversion time was adjusted to null
the signal from viable myocardium [17].
CMR analysis
All analyses were performed by consensus of independent
blinded observers on an off-line workstation (View Forum, Philips
Medical Systems).
On cine CMR, for quantiﬁcation of LV volumes and LV ejection
fraction (EF), endocardial borders were delineated on the end-
diastolic and end-systolic short-axis slices.
On LGE-CMR, we assessed the presence of infarct area and
MVO. We calculated infarct size by automatic summation of
all slice volumes of infarct area and expressed as a percentage of
LV volume [18]. According to a previous study [19], the infarct
area was deﬁned as the area with signal intensity 5 SDs above
the mean signal obtained in the remote noninfarcted myocardi-
um on LGE images. MVO was detected as the area with
hypointense core within LGE, which was included in the area of
infarction [20].
Statistical analysis
All statistical analyses were carried out using SPSS version 11.0
(SPSS, Chicago, IL, USA). Categorical variables were presented as
frequency counts and percentages, with comparison with chi-
square statistics. Continuous variables were presented as median
and interquartile range and compared using the Mann–Whitney U
test. A multivariable logistic regression analysis was used to
determine predictors of MVO. The model included clinical and
angiographic characteristics with p < 0.05 in the univariate
analyses. Receiver operating characteristics (ROC) curve analysis
was performed to establish glucose level at admission as a
predictor of MVO. The resulting sensitivity, speciﬁcity and area
under curve (AUC) were calculated. The best cut-off value was
determined by the maximum sum of sensitivity and speciﬁcity.
The relationship between glucose level at admission and infarct
size was analyzed by Pearson correlation analysis. A p-value <0.05
was considered statistically signiﬁcant.
Table 2
Cardiovascular magnetic resonance imaging ﬁndings.
MVO group No-MVO group p-value
n = 34 n = 59
LV ejection fraction, % 43 [36–51] 48 [43–55] 0.055
LV end-diastolic volume, ml 129 [105–148] 121 [98–136] 0.180
LV end-systolic volume, ml 65 [54–89] 59 [47–75] 0.134
Infarct size, % 20 [13–30] 15 [8–20] 0.031
Values are given as median [interquartile range]. LV, left ventricular; MVO,
microvascular obstruction.
Table 3
A multivariable logistic regression analysis as predictor of MVO.
OR 95% CI p-value
Glucose level at admission 1.014 1.004–1.023 0.006
Peak CK-MB 1.007 1.003–1.012 0.002
No reﬂow, post-TIMI grade 0/1/2 9.311 1.067–81.26 0.044
Age – – 0.164
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Patient’s clinical and angiographic characteristics
Adequate CMR was obtained in all patients. CMR-derived MVO
was seen in 34 patients (37%). Patients’ clinical and angiographic
characteristics are summarized in Table 1. Age, reperfusion injury, no
reﬂow phenomenon, and peak CK-MB levels were different between
the MVO group and the no-MVO group. Moreover, glucose level at
admission of the MVO group was signiﬁcantly higher than that of the
no-MVO group [204 (153–267) mg/dl vs. 157 (127–200) mg/dl,
p = 0.002] (Table 1, Fig. 1). There were no differences in glycosylated
hemoglobin and incidence of DM between the two subjects.
CMR ﬁndings
CMR ﬁndings are shown in Table 2. Although there were no
differences in LVEF, LV end-diastolic volume, and LV end-systolicTable 1
Patient clinical and angiographic characteristics.
MVO group No-MVO group p-value
n = 34 n = 59
Age, years 64 [55–71] 70 [63–77] 0.015
Male 26 (76) 46 (78) 0.868
Hypertension 25 (74) 41 (69) 0.679
Diabetes mellitus 16 (47) 18 (31) 0.110
Dyslipidemia 19 (56) 32 (54) 0.878
Current smoker 18 (53) 37 (63) 0.356
Glucose level at
admission, mg/dl
204 [153–267] 157 [127–200] 0.002
HbA1c, % 5.9 [5.3–6.8] 5.6 [5.1–6.2] 0.07
Killip class 32 5 (15) 6 (10) 0.368
Symptom onset to
reﬂow time, h
6.5 [5–10.5] 5.2 [3–15] 0.877
Pre-infarction angina 7 (21) 15 (25) 0.597
Anterior wall infarction 15 (44) 26 (44) 0.996
Good collaterals,
Rentrop grade 2/3
5 (15) 8 (14) 0.554
Aspiration thrombectomy 31 (91) 56 (95) 0.788
Reperfusion injury 16 (47) 14 (24) 0.020
No reﬂow, post-TIMI
grade 0/1/2
10 (29) 3 (5) 0.002
Peak CK-MB, IU/L 373 [223–501] 193 [79–276] <0.001
Values are given as median [interquartile range] or n (%). CK-MB, creatine kinase
myocardial band; HbA1c, glycosylated hemoglobin; MVO, microvascular
obstruction; TIMI, thrombolysis in myocardial infarction.
Fig. 1. Relationship between glucose level at admission and MVO. Glucose level at
admission of MVO Group was signiﬁcantly higher than that of No-MVO Group.
MVO, microvascular obstruction.
Reperfusion injury – – 0.592
Infarct size assessed by CMR – – 0.514
CI, conﬁdence interval; CK-MB, creatine kinase myocardial band; CMR,
cardiovascular magnetic resonance imaging; MVO, microvascular obstruction;
OR, odds ratio; TIMI, thrombolysis in myocardial infarction.volume between the two groups, infarct size was signiﬁcantly
greater in the MVO group compared with the no-MVO group
[20 (13–30)% vs. 15 (8–20)%, p = 0.031].
A multivariable logistic regression analysis
The glucose level at admission, peak CK-MB, and no reﬂow
phenomenon were independent predictors of MVO (odds ratio,
1.014; 95% conﬁdence interval, 1.004 to 1.023; p = 0.006, odds
ratio, 1.007; 95% conﬁdence interval, 1.003 to 1.012; p = 0.002 and
odds ratio, 9.311; 95% conﬁdence interval, 1.067 to 81.26;
p = 0.044, respectively) (Table 3). Age, reperfusion injury, and
infarct size assessed by CMR did not correlate with MVO in this
model. A representative case with MVO assessed by LGE-CMR
is shown in Fig. 2.
Prediction of the occurrence of MVO
ROC curve analysis was used to identify optimal cut-off value of
glucose level at admission that best predicted MVO. The glucose
level at admission 190 mg/dl (sensitivity 53%, speciﬁcity 73%,
AUC = 0.69) was the best threshold value for identifying MVO. The
occurrence of MVO was signiﬁcantly higher in the patients with
glucose level at admission 3190 mg/dl compared with the
patients with glucose level <190 mg/dl [18 (53%) vs. 16 (27%),
p = 0.023].
Relationship between glucose level at admission and infarct size
The relationship between glucose level at admission and infarct
size assessed by LGE-CMR was analyzed. There was no correlation
between glucose level at admission and infarct size assessed by
LGE-CMR (r = 0.095, p = 0.451).
Discussion
In the present study, we investigated the relationship between
hyperglycemia at admission and MVO assessed by LGE-MRI in
93 patients with STEMI. The patients with MVO showed a higher
blood glucose level at admission than those without it, whereas
the DM frequency and HbA1c values were not different between
Fig. 2. Representative case of CMR-derived MVO. (A) Angiography before PCI demonstrated a total occlusion in the RCA. (B) An infarct-related lesion was successfully
recanalized by PCI. (C, D) LGE-CMR demonstrated MVO in the inferior wall (arrows). The glucose level at admission was 331 mg/dl. CMR, cardiovascular magnetic resonance
imaging; LGE, late gadolinium enhancement; MVO, microvascular obstruction; PCI, percutaneous coronary intervention; RCA, right coronary artery.
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than those without it. The major ﬁnding in this study was that
hyperglycemia at admission was an independent predictor of
CMR-derived MVO. The glucose level at admission 190 mg/dl was
the best cut-off value for identifying MVO.
Hyperglycemia with AMI is associated with an increased risk
of in-hospital mortality in patients with and without DM [11].
In addition, it has been reported that there is a linear positive
relationship between blood glucose level and mortality [21]. As
the underlying mechanisms of these deleterious effects of
hyperglycemia, a previous study showed the association between
hyperglycemia at admission and microvascular dysfunction using
myocardial contrast echocardiography [13]. This study conﬁrmed
the association between hyperglycemia at admission and MVO
assessed by CMR.
Several mechanisms might explain the association between
hyperglycemia and MVO. Acute hyperglycemia also increases
intercellular adhesion molecule-1 levels [22] or P-selectin [23],
which would augment plugging of leukocytes in the capillaries.
Plugging of enhanced leukocytes in the microcirculation might
further contribute to the no-reﬂow phenomenon [24]. Leuko-
cytes trapped in the coronary capillaries and venules early after
coronary reperfusion are more frequently observed in the
diabetic rat heart than in the non-diabetic heart [25]. In this
study, infarct size of the patients with MVO was larger than that
of non-MVO. Large infarcts are more likely to cause catechol-
amine release, which is known to affect glucose homeostasis.
However, there was no correlation between glucose level at
admission and infarct size.MVO occurs in a sizable proportion of AMI patients despite
successful epicardial recanalization of the infarct-related artery
[26,27]. Severe MVO may lead to overt reduction in ﬂow in the
patent upstream epicardial arteries, which is termed no reﬂow
phenomenon. LGE-CMR directly visualized and sensitively
detects MVO [28]. Previous studies demonstrated that MVO
assessed by LGE-CMR was associated with worse clinical
outcomes in patients with AMI. Rubenstein et al. showed that
MVO predicted greater myocardial damage and worse LV
function after AMI [29]. Nijiveldt et al. revealed that MVO
was related to adverse LV remodeling and lack of functional
improvement [28]. deWaha et al. showed that MVO was an
independent predictor of major adverse cardiac events in
STEMI patients [26]. In the present study, the patients with
MVO showed a larger infarct size than those without MVO,
which was compatible with a previous study [26]. The presence
of MVO signiﬁcantly increases with infarct transmurality. On the
other hand, circumferential endocardial extent of myocardial
infarction is related to the myocardial supply area of infarct-
related artery. Thus, infarct size correlates with not only the
presence of MVO but also the myocardial supply area of infarct-
related artery [30]. This may explain the poor correlation
between infarct size by LGE-CMR and MVO in the present
multivariate regression analysis.
MVO correlates with poorer LV function and more frequent
post-AMI complications, however the predictors and prevention
of MVO after primary PCI have not yet been fully investigated.
Previous studies reported the association between plaque char-
acteristics and incidence of MVO [31,32]. Several mechanical
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of primary PCI. Initial small trials of aspiration thrombectomy
reported conﬂicting results [33,34]. Kaltoft et al. reported that
thrombectomy did not improve ST-segment resolution and was
associated with increased infarct size [34]. Conversely, in the
REMEDIA (Randomized Evaluation of the Effect of Mechanical
Reduction of Distal Embolization by Thrombus-Aspiration in
Primary and Rescue Angioplasty) study [33], thrombectomy
improved microvascular perfusion. In this study, aspiration
thrombectomy was not associated with incidence of MVO. Several
medications such as nicorandil, which improve microvascular
perfusion [35], were not routinely administered in the present
study.
In this study, we demonstrated that hyperglycemia at admis-
sion was one of the independent predictors of MVO assessed by
LGE-MRI. Thus, the measurement of glucose level at admission
might be useful for risk stratiﬁcation in STEMI patients undergoing
primary PCI.
Study limitations
There were several limitations in the present study. First, we did
not assess how the glucose level had changed before coronary
reperfusion. Second, we also did not investigate how long hypergly-
cemia persisted before reperfusion. Third, we did not evaluate the
association between plaque characteristics and MVO. Finally, this
study was a retrospective observational study. Further prospective
studies are required to determine the effect of hyperglycemia on
MVO and the effect of controlling blood glucose level on MVO.
Conclusions
Hyperglycemia at admission in STEMI patients who were
treated by primary PCI was associated with the presence of MVO
assessed by LGE-CMR. The measurement of glucose level at
admission might be useful for risk stratiﬁcation in STEMI patients
undergoing primary PCI.
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